Kyoichi Kaira1,2, Mitsuhiro Kamiyoshihara3, Osamu Kawashima4, Hideki Endoh5, Kazuyoshi Imaizumi6, Masayuki Sugano7, Shigefumi Tanaka8, Atsushi Fujita9, Yoshihito Kogure10, Akira Shimizu11, Tetsunari Oyama12, Takayuki Asao13, Kimihiro Shimizu14, Akira Mogi14. 1. Department of Oncology Clinical Development, Gunma University Graduate School of Medicine, Maebashi, Japan kkaira1970@yahoo.co.jp. 2. Department of Respiratory Medicine, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Hidaka, Japan. 3. Department of Respiratory Surgery, Maebashi Red Cross Hospital, Maebashi, Japan. 4. Department of Respiratory Surgery, Shibukawa Medical Center, Shibukawa, Japan. 5. Department of Thoracic Surgery, Saku Central Hospital Advanced Care Center, Saku, Japan. 6. Department of Respiratory Medicine, Fujita Health University, Toyoake, Japan. 7. Department of Respiratory Surgery, Takasaki Medical Center, Takasaki, Japan. 8. Department of Respiratory Surgery, Isesaki Municipal Hospital, Isesaki, Japan. 9. Division of Respiratory Surgery, Gunma Prefectural Cancer Center, Ota, Japan. 10. Department of Respiratory Medicine, Nagoya Medical Center, Nagoya, Japan. 11. Department of Dermatology, Gunma University Graduate School of Medicine, Maebashi, Japan. 12. Department of Diagnostic Pathology, Gunma University Graduate School of Medicine, Maebashi, Japan. 13. Big Data Center for Integrative Analysis, Gunma University Initiative for Advance Research, Maebashi, Japan. 14. Division of Respiratory Surgery, Integrative Center of General Surgery, Gunma University Hospital, Maebashi, Japan.
Abstract
BACKGROUND/AIM: The β2-adrenergic receptor (β2AR) is highly expressed in various human cancers and has been linked to tumor growth and metastases. Although β2AR is considered a novel therapeutic target of human neoplasms, the clinicopathological significance of β2AR expression in patients with pulmonary pleomorphic carcinoma (PPC) remains unclear. The aim of this study was to clarify the prognostic impact of β2AR in PPC. PATIENTS AND METHODS: One hundred and five Japanese patients with surgically resected PPC were included in the study. The expression levels of β2AR were assessed by immunohistochemistry in specimens from the resected tumors, and their association with patient survival, as well as with tumor characteristics was investigated. RESULTS: β2AR was highly expressed in 63% of all patients, irrespective of adenocarcinoma components present. The β2AR expression was significantly associated with lymph node metastasis, lymphatic permeation and tumor cell proliferation in PPC patients with early-stage disease (stage I or II). A high β2AR expression was identified as a significant predictor of worse prognosis for PPC patients during early stages of the disease. Multivariate analysis confirmed that β2AR expression was an independent factor for predicting the overall survival of PPC patients. CONCLUSION: β2AR can serve as a significant predictor of tumor aggressiveness and poor survival for PPC patients, especially those with early-stage disease. Copyright
BACKGROUND/AIM: The β2-adrenergic receptor (β2AR) is highly expressed in various humancancers and has been linked to tumor growth and metastases. Although β2AR is considered a novel therapeutic target of humanneoplasms, the clinicopathological significance of β2AR expression in patients with pulmonary pleomorphic carcinoma (PPC) remains unclear. The aim of this study was to clarify the prognostic impact of β2AR in PPC. PATIENTS AND METHODS: One hundred and five Japanese patients with surgically resected PPC were included in the study. The expression levels of β2AR were assessed by immunohistochemistry in specimens from the resected tumors, and their association with patient survival, as well as with tumor characteristics was investigated. RESULTS: β2AR was highly expressed in 63% of all patients, irrespective of adenocarcinoma components present. The β2AR expression was significantly associated with lymph node metastasis, lymphatic permeation and tumor cell proliferation in PPC patients with early-stage disease (stage I or II). A high β2AR expression was identified as a significant predictor of worse prognosis for PPC patients during early stages of the disease. Multivariate analysis confirmed that β2AR expression was an independent factor for predicting the overall survival of PPC patients. CONCLUSION: β2AR can serve as a significant predictor of tumor aggressiveness and poor survival for PPC patients, especially those with early-stage disease. Copyright